Mechanism of Action
L-Carnitine's primary function is as a mitochondrial shuttle for long-chain fatty acids, with secondary roles in buffering acyl-CoA toxicity and modulating metabolic flexibility.
Fatty Acid Transport (Primary Role)
Long-chain fatty acids (>10 carbons) cannot cross the inner mitochondrial membrane in free form. L-Carnitine binds to long-chain acyl-CoA esters via carnitine palmitoyltransferase I (CPT1) on the outer mitochondrial membrane, forming acylcarnitine. The acylcarnitine complex crosses the inner membrane via the carnitine-acylcarnitine translocase (CACT), where CPT2 releases the acyl group back to CoA inside the matrix for beta-oxidation and ATP generation.[1]Acyl-CoA Buffering
L-Carnitine shuttles excess acyl groups (formed during fatty acid oxidation, amino acid catabolism, and organic acid metabolism) out of the mitochondria as acylcarnitine esters, preventing toxic intramitochondrial CoA sequestration. This buffering role is critical in organic acidemias and during states of metabolic stress where acyl-CoA accumulation would otherwise halt the TCA cycle.[2]Glucose Oxidation Modulation
By facilitating fatty acid oxidation, L-Carnitine indirectly regulates glucose utilization. In states of adequate carnitine, the cell preferentially oxidizes fatty acids. In carnitine deficiency, the cell shifts toward glucose oxidation and lactate production, contributing to metabolic acidosis and fatigue.Research Overview
Carnitine Deficiency (FDA-Approved)
FDA ApprovedPrimary systemic carnitine deficiency (genetic carnitine transporter defect, SLC22A5 mutations) causes severe cardiomyopathy, skeletal myopathy, and hypoglycemia. IV/oral Levocarnitine is the standard of care and is life-saving. Secondary deficiencies occur in inborn errors of metabolism (VLCAD, MCAD, propionic acidemia) and in hemodialysis patients who lose carnitine during dialysis sessions.[1]
Cardiovascular Health
Strong Clinical EvidenceA 2013 meta-analysis of 13 randomized controlled trials (n=3,629) found L-Carnitine supplementation significantly reduced all-cause mortality (27% reduction), ventricular arrhythmias (65% reduction), and anginal symptoms following acute myocardial infarction. Propionyl-L-Carnitine has demonstrated efficacy in peripheral arterial disease, improving walking distance and reducing claudication pain in multiple Phase III trials.[3]
Metabolic & Insulin Sensitivity
Phase II/III ClinicalL-Carnitine supplementation improves insulin-mediated glucose disposal in type 2 diabetic patients, likely by reducing intramyocellular lipid accumulation and improving mitochondrial function. Several trials demonstrate reduced HbA1c, improved lipid profiles, and reduced oxidative stress markers with intravenous Levocarnitine in diabetic and metabolic syndrome populations.[4]
Male Fertility
Consistent EvidenceL-Carnitine and Acetyl-L-Carnitine are highly concentrated in the epididymis and are essential for sperm maturation and motility. Multiple randomized trials demonstrate improved sperm motility, morphology, and pregnancy rates with L-Carnitine supplementation in infertile men with asthenozoospermia. Combined L-Carnitine + Acetyl-L-Carnitine protocols show the strongest results.[5]
Exercise Performance
Mixed EvidenceThe evidence for L-Carnitine as a performance enhancer in healthy, adequately nourished subjects is inconsistent. Some studies show improved VO2 max, reduced lactate accumulation, and faster recovery markers; others show no significant effect. Benefits appear more pronounced in populations with relative carnitine insufficiency (vegetarians, elderly, patients with metabolic disease).[6]
Calculate your L-Carnitine dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic support / general | 1000 mg | Daily | IM or IV |
| Cardiovascular / post-cardiac event | 2000–3000 mg | Daily | IV infusion |
| ESRD / hemodialysis support | 10–20 mg/kg | After each dialysis session | IV bolus (slow) |
| Male fertility | 1000–2000 mg | Daily | IM or oral |
| Performance / recovery | 500–1000 mg | 3x/week | IM |
Injectable Levocarnitine (200 mg/mL) is a pre-mixed solution requiring no reconstitution. For IM administration, inject slowly into a large muscle (glute or lateral thigh). IV administration should be done as a slow bolus over 2–3 minutes or by infusion. Morning dosing is preferred for metabolic applications. Hemodialysis patients receive their dose after each dialysis session to replace dialysis-induced losses.
Research protocols only. Not medical advice.
Peptide & Supplement Interactions
Safety Profile
Injectable Levocarnitine has an excellent safety profile with decades of clinical use data. It is endogenous and the body has robust regulatory mechanisms for carnitine homeostasis.
Gastrointestinal effects: The most common adverse effects are nausea, vomiting, and body odor (fishy smell due to TMAO production from gut bacteria), primarily seen with oral, not injectable, forms.
Injectable tolerability: IV/IM Levocarnitine is well tolerated. Rapid IV bolus can cause transient nausea; slow administration (over 2–3 minutes) minimizes this.
D-Carnitine antagonism: D-Carnitine (the inactive isomer, sometimes present in racemic mixtures) competitively inhibits L-Carnitine transport. Only use L-Carnitine (Levocarnitine); pharmaceutical-grade injectable preparations contain only the L-isomer.
Seizure risk (rare): Case reports exist of seizures in patients with pre-existing seizure disorders. Use with caution in epilepsy.
No WADA prohibition: L-Carnitine is not on the WADA Prohibited List for any sport.
References
- [1]Longo N, et al. "Disorders of carnitine transport and the carnitine cycle." Am J Med Genet C Semin Med Genet. 2006;142C(2):77-85.
- [2]Rinaldo P, et al. "Fatty acid oxidation disorders." Annu Rev Physiol. 2002;64:477-502.
- [3]DiNicolantonio JJ, et al. "L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis." Mayo Clin Proc. 2013;88(6):544-51.
- [4]Mingrone G. "Carnitine in type 2 diabetes." Ann N Y Acad Sci. 2004;1033:99-107.
- [5]Lenzi A, et al. "A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia." Fertil Steril. 2004;81(6):1578-84.
- [6]Brass EP. "Supplemental carnitine and exercise." Am J Clin Nutr. 2000;72(2 Suppl):618S-23S.